M&A Deal Summary |
|
|---|---|
| Date | 2012-02-17 |
| Target | Amsterdam Molecular Therapeutics Holding N.V. |
| Sector | Life Science |
| Buyer(s) | uniQure |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1998 |
| Sector | Life Science |
| Employees | 480 |
| Revenue | 16M USD (2023) |
uniQure is a gene therapy company that developed the first and only gene therapy product to receive regulatory approval in the European Union. Gene therapy is a technique for correcting defective or missing genes that cause diseases. uniQure is primarily focused on rare genetic diseases, and will also start developing gene therapies for chronic and degenerative diseases that affect larger populations. uniQure was founded in 1998 and is based in Amsterdam, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector (Life Science) | 1 of 3 |
| Type (Add-on Acquisition) | 1 of 3 |
| Country (Netherlands) | 1 of 1 |
| Year (2012) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-08-11 |
InoCard
Heidelberg, Germany InoCard GmbH is a biotechnology company focused on the development of gene therapy approaches for cardiac disease. |
Buy | €3M |
